{"id":"chop-plus-famotidine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL902","moleculeType":"Small molecule","molecularWeight":"337.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CHOP is a standard multi-agent chemotherapy regimen used in lymphoma treatment that works through DNA alkylation, topoisomerase inhibition, and microtubule disruption. Famotidine is added to reduce chemotherapy-induced gastrointestinal toxicity by suppressing gastric acid production via H2-receptor antagonism, potentially improving tolerability and allowing better chemotherapy delivery.","oneSentence":"CHOP Plus Famotidine combines cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP chemotherapy) with famotidine, a histamine H2-receptor antagonist, to enhance chemotherapy efficacy and reduce gastric toxicity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:55.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoma (specific subtype under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT03647072","phase":"PHASE3","title":"PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2018-08-01","conditions":"Lymphoma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CHOP Plus Famotidine 40"],"phase":"phase_3","status":"active","brandName":"CHOP Plus Famotidine","genericName":"CHOP Plus Famotidine","companyName":"Sherief Abd-Elsalam","companyId":"sherief-abd-elsalam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHOP Plus Famotidine combines cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP chemotherapy) with famotidine, a histamine H2-receptor antagonist, to enhance chemotherapy efficacy and reduce gastric toxicity. Used for Lymphoma (specific subtype under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}